ClinicalTrials.gg
CompletedNCT04480463Updated Oct 10, 2023Results posted

A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)

A Phase 3 interventional study of SCD411 and Aflibercept in Wet Age-related Macular Degeneration and Neovascular Age-related Macular Degeneration, sponsored by Sam Chun Dang Pharm. Co. Ltd.. Completed at 130 sites in 14 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Sam Chun Dang Pharm. Co. Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
576
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies in Macular Degeneration with a site in Korea, Republic of — 11 open to participants now, 13 under way, 5 of them phase 3. Macular Degeneration · Korea, Republic of.

Enrollment
10th of 56
576 · median 81
Started
2020
with 5 others
Phase 3
22 of 67
4 open now
Registered
37th of 67
by date

Among the 67 studies in Macular Degeneration with a site in Korea, Republic of, this one is the 10th largest by enrollment of the 56 interventional ones that give a count, is one of 6 that started in 2020, is one of 22 in phase 3, and was the 37th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

11 of the 67 studies in Macular Degeneration with a site in Korea, Republic of are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Macular Degeneration with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting vision. The current standard of care for patients with neovascular (exudative / wet) AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy, which prevents or slows down the growth of the abnormal blood vessels. SCD411 is being developed as a biosimilar to the reference product Eylea® (aflibercept), an anti-VEGF drug. The study aims to prove equivalence of SCD411 to Eylea in adults with wet AMD, and will look at safety, tolerance, effectiveness, immune response and the movement of the drug through the body.

03

Conditions studied

  • Wet Age-related Macular Degeneration
  • Neovascular Age-related Macular Degeneration

Keywords

  • Age-related macular degeneration
  • AMD
  • Neovascular
  • Exudative
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provides written .
  • Clinical diagnosis of wet (neovascular) age-related macular degeneration (AMD).
  • BCVA (best corrected visual acuity) letter score of 73 to 35 at screening and prior to randomization. In addition, fellow eye should not be less than 35 letter score using the ETDRS chart or 2702 series number chart.
  • Women of with negative serum pregnancy test at screening must agree to use protocol-defined methods of throughout study until 3 months after last injection of aflibercept/SCD411.
  • Males with female partners of child-bearing potential must agree to use protocol-defined methods of contraception and refrain from donating sperm throughout study until 3 months after last injection of aflibercept/SCD411.

Exclusion criteria

Exclusion Criteria:

  • Any prior eye (study eye and fellow eye) or systemic treatment or surgery for neovascular AMD, except dietary supplements or vitamins.
  • Any prior or current treatment with another agent to great neovascular AMD in the study eye, except dietary supplements or vitamins.
  • Fellow eye shows signed of AMD that may need treatment during study period.
  • Any prior treatment with anti-VEGF agents in both eyes.
  • Total lesion size >30.5 mm2, Blood, scars, atrophy, fibrosis, and neovascularization, based on assessment at screening.
  • Central retina thickness of \<300 µm in the study eye.
  • Subretinal hemorrhage that is either 50% or more of the total lesion area.
  • Scar or fibrosis making up >50% of the total lesion.
  • Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
  • Presence of retinal pigment epithelial tears or rips involving the macular in the study eye.
  • Cataract in the study eye that have Lens Opacity Classification System II (LOCS II) grade IV cataract in the study eye or in the Investigator's opinion, interferes with visualization of retina or retinal imaging.
  • Inflammation outside the eyeball in either eye, or within the eyeball of the study eye.
  • History of any vitreous hemorrhage in the study eye.
  • History or clinical evidence of diabetic retinopathy, diabetic macular edema, or any other vascular disease.
  • History of, treatment or surgery for detached retina.
  • History of uncomplicated surgery within the eyeball or around the study eye, except lid surgery.
  • Absence of lens in study eye.
  • Uncontrolled hypertension, defined as systolic blood pressure (BP) >160 mmHg or diastolic BP >100 mmHg under appropriate antihypertensive treatment.
  • to aflibercept or medications used in the study (fluorescein, mydriatic eye drops, etc.).
  • Pregnancy or lactation at Screening or at baseline for women of .
  • History of blood clotting events.
  • History or evidence of cardiac conditions, or inability to perform any physical activity without discomfort; ventricular arrhythmia; and atrial fibrillation.
  • History of laser therapy in the macular region.
  • Any prior or current treatment with inside or immediately around the study eye.
  • Any prior or current treatment involving the macula with photodynamic therapy (PDT) with verteporfin, transpupillary thermotherapy, radiation therapy, or retinal laser treatment in the study eye.
  • Any prior or current treatment with pan-retinal photocoagulation.
  • Any prior or current treatment with ethambutol; deferoxamine and topiramate; tamoxifen, hydroxychloroquine, chloroquine, or vigabatrin; and amiodarone.
  • Any investigational product for the treatment of eye conditions and systemic conditions, 30 days or 5 half-lives (whichever is longer), prior to randomization, and throughout the study, except dietary supplements or vitamins.
  • Intraocular pressure ≥25 mmHg in spite of anti-glaucoma treatment.
  • Any prior or ongoing systemic medical condition (including but not limited to infectious, inflammatory, psychiatric, neurological, renal, hepatic, respiratory conditions or ) or screening laboratory value that in the opinion of the investigator may present a safety risk, interfere with study compliance and follow-up, or confound data interpretation throughout the study period.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
576 participants (actual)

Study arms

  • Experimental
    SCD411

    Drug: SCD411

  • Active comparator
    Aflibercept

    Drug: Aflibercept

Interventions

  • DrugSCD411

    IVT (intravitreal) injection

  • IVT injection

    Also known as: Eylea®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in BCVA (Best Corrected Visual Acuity)

    Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score or 2702 charts

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Change From Baseline in BCVA (Best Corrected Visual Acuity)

    Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score or 2702 charts

    Time frame: Baseline to Week 52

  2. Percentage of Subjects With Anti-SCD411 Antibodies

    Assessed by blood samples

    Time frame: Baseline, Weeks 4, 8, 20, 36 and 52

07

Results

Posted Oct 10, 2023

Participant flow

Participant flow — Overall Study
MilestoneSCD411Aflibercept
Started288288
Completed259256
Not completed2932
Withdrew: Death01
Withdrew: Adverse event68
Withdrew: Lost to follow-up32
Withdrew: Physician decision25
Withdrew: Decision by the sponsor or administrative decision for a reason other than that of an ae23
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject67
Withdrew: Subject missed any of first 2 doses (ivt i injection of ip at day 1 or week 4) after randomization01
Withdrew: A decrease in bcva of ≥30 letters compared with the last assessment of va10
Withdrew: Subretinal hemorrhage involving center of fovea or, size of hemorrhage was ≥50% of total lesion area10
Withdrew: Other64

Outcome measures

PrimaryChange From Baseline in BCVA (Best Corrected Visual Acuity)

Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score or 2702 charts

Time frame:
Baseline to Week 8
Reported as:
Mean · Letters correctly read
Change From Baseline in BCVA (Best Corrected Visual Acuity)
Letters correctly readSCD411Aflibercept
Change From Baseline in BCVA (Best Corrected Visual Acuity)5.5 (4.5 to 6.5)5.9 (4.8 to 6.9)
SecondaryChange From Baseline in BCVA (Best Corrected Visual Acuity)

Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letters score or 2702 charts

Time frame:
Baseline to Week 52
Reported as:
Mean · Letters correctly read
Change From Baseline in BCVA (Best Corrected Visual Acuity)
Letters correctly readSCD411Aflibercept
Change From Baseline in BCVA (Best Corrected Visual Acuity)9.0 (7.6 to 10.4)7.7 (6.3 to 9.1)
SecondaryPercentage of Subjects With Anti-SCD411 Antibodies

Assessed by blood samples

Time frame:
Baseline, Weeks 4, 8, 20, 36 and 52
Reported as:
Number · Percentage of participants
Percentage of Subjects With Anti-SCD411 Antibodies
Percentage of participantsSCD411
Baseline : Positive7.1
Baseline : Negative92.9
Week 4 : Positive29.4
Week 4 : Negative70.6
Week 8 : Positive40.0
Week 8 : Negative60.0
Week 20 : Positive39.6
Week 20 : Negative60.4
Week 36 : Positive22.9
Week 36 : Negative77.1
Week 52 : Positive20.2
Week 52 : Negative79.8

Adverse events

Collected over Adverse events were assessed beginning at enrollment (date of signed informed consent) and up to 28 days after the last dose of the study drug, up to Day 365.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SCD4110/287 (0%)32/287 (11.1%)128/287 (44.6%)
Aflibercept1/286 (0.3%)30/286 (10.5%)121/286 (42.3%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventSCD411Aflibercept
Angina pectorisCardiac disorders0/2872/286
Visual acuity reducedEye disorders2/2871/286
Retinal pigment epithelial tearEye disorders2/2870/286
COVID-19Infections and infestations2/2871/286
PneumoniaInfections and infestations2/2870/286
Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders2/2870/286
Amaurosis fugaxEye disorders0/2871/286
Retinal haemorrhageEye disorders0/2871/286
Visual acuity reducedEye disorders0/2871/286
Autoimmune haemolytic anaemiaBlood and lymphatic system disorders0/2871/286
Most frequent other events
Showing 10 of 53
Most frequent other events
EventSCD411Aflibercept
COVID-19Infections and infestations16/28721/286
Neovascular age-related macular degenerationEye disorders20/28713/286
Visual acuity reducedEye disorders11/28712/286
HypertensionVascular disorders11/2874/286
Back painMusculoskeletal and connective tissue disorders9/28710/286
Urinary tract infectionInfections and infestations10/2877/286
Conjunctival haemorrhageEye disorders8/2876/286
ConjunctivitisInfections and infestations7/2872/286
ArthralgiaMusculoskeletal and connective tissue disorders3/2876/286
NasopharyngitisInfections and infestations6/2871/286

Baseline characteristics

Included all randomized subjects who received at least 1 injection of the IP. Numbers were based on planned treatment group. Two subjects met the exclusion criteria but were randomized in error; however, they did not receive any IP injection. A third subject also did not receive any IP injection. These 3 subjects were excluded from all analyses sets.

Age, Continuous
Age, Continuous(years)SCD411AfliberceptTotal
Mean73.5 ± 873.6 ± 8.5573.5 ± 8.27
Age, Customized
Age, Customized(Participants)SCD411AfliberceptTotal
50 to less than 65 years334073
65 to less than 75 years131119250
Greater than or equal to 75 years123127250
Sex: Female, Male
Sex: Female, Male(Participants)SCD411AfliberceptTotal
Female149147296
Male138139277
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SCD411AfliberceptTotal
Hispanic or Latino91019
Not Hispanic or Latino278276554
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SCD411AfliberceptTotal
American Indian or Alaska Native112
Asian9790187
Native Hawaiian or Other Pacific Islander000
Black or African American112
White188194382
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)SCD411AfliberceptTotal
Australia7613
Bulgaria224
Czechia336
Hungary221739
India819
Israel424284
Japan303060
Latvia101323
Poland375087
South Korea5959118
Russia121022
Slovakia161329
Spain202444
United States191635
Weight
Weight(kilograms)SCD411AfliberceptTotal
Mean72.39 ± 15.24472.26 ± 12.28072.32 ± 14.757
Height
Height(centimeters)SCD411AfliberceptTotal
Mean164.02 ± 9.117164.64 ± 8.976164.33 ± 9.045

2 further baseline measures are reported on the registry.

08

Study locations

130 sites
  • SCD Research Site
    Campbell, California 95008, United States
  • SCD Research Site
    Clearwater, Florida 33761, United States
  • SCD Research Site
    Coral Springs, Florida 33067, United States
  • SCD Research Site
    Fort Myers, Florida 33912, United States
  • SCD Research Site
    Stuart, Florida 34994, United States
  • SCD Research Site
    Marietta, Georgia 30060, United States
  • SCD Research Site
    Lemont, Illinois 60439, United States
  • SCD Research Site
    Liverpool, New York 13088, United States
  • SCD Research Site
    Springfield, Oregon 97477, United States
  • SCD Research Site
    Rapid City, South Dakota 57701, United States
  • SCD Research Site
    Abilene, Texas 79606, United States
  • SCD Research Site
    Willow Park, Texas 76087, United States
  • SCD Research Site
    Liverpool, New South Wales 2170, Australia
  • SCD Research Site
    Sydney, New South Wales 2000, Australia
  • SCD Research Site
    East Melbourne, Victoria 3002, Australia
  • SCD Research Site
    Nedlands, Western Australia 6009, Australia
  • SCD Research Site
    Sofia, Sofia-Grad 1431, Bulgaria
  • SCD Research Site
    Sofia, Sofia-Grad 1784, Bulgaria
  • SCD Research Site
    Sofia, 1618, Bulgaria
  • SCD Research Site
    Pardubice, Pardubicky Kraj 530 02, Czechia
  • SCD Research Site
    Praha, 128 08, Czechia
  • SCD Research Site
    Budapest, 1062, Hungary
  • SCD Research Site
    Budapest, 1085, Hungary
  • SCD Research Site
    Budapest, 1133, Hungary
  • SCD Research Site
    Budapest, 1204, Hungary
  • SCD Research Site
    Debrecen, 4032, Hungary
  • SCD Research Site
    Nyíregyháza, 4400, Hungary
  • SCD Research Site
    Pécs, 7621, Hungary
  • SCD Research Site
    Wardha, Maharashtra 442001, India
  • SCD Research Site
    Bhubaneswar, Orissa 751024, India
  • SCD Research Site
    Jaipur, Rajasthan 302015, India
  • SCD Research Site
    Hyderabad, Telangana 500018, India
  • SCD Research Site
    Lucknow, Uttar Pradesh 226001, India
  • SCD Research Site
    Kolkata, West Bengal 700020, India
  • SCD Research Site
    Kolkata, West Bengal 700073, India
  • SCD Research Site
    Haifa, 31096, Israel
  • SCD Research Site
    Haifa, 34362, Israel
  • SCD Research Site
    H̱olon, 58100, Israel
  • SCD Research Site
    Jerusalem, 91120, Israel
  • SCD Research Site
    Kfar Saba, 44281, Israel
  • SCD Research Site
    Nahariya, 22100, Israel
  • SCD Research Site
    Petah tikva, 49100, Israel
  • SCD Research Site
    Ramat Gan, 52621, Israel
  • SCD Research Site
    Reẖovot, 76100, Israel
  • SCD Research Site
    Tel Aviv, 64239, Israel
  • SCD Research Site
    Tiberias, 15208, Israel
  • SCD Research Site
    Zerifin, 70300, Israel
  • SCD Research Site
    Nagoya, Aiti 457-8510, Japan
  • SCD Research Site
    Kurume, Hukuoka 830-0011, Japan
  • SCD Research Site
    Kobe, Hyogo 650-0047, Japan
  • SCD Research Site
    Nishinomiya, Hyogo 663-8501, Japan
  • SCD Research Site
    Amagasaki, Hyôgo 660-8550, Japan
  • SCD Research Site
    Kagoshima, Kogosima 890-8520, Japan
  • SCD Research Site
    Kyoto, Kyôto 607-8062, Japan
  • SCD Research Site
    Nakagami, Okinawa 903-0215, Japan
  • SCD Research Site
    Chuo Ku, Tokyo 104-8560, Japan
  • SCD Research Site
    Hachiōji, Tokyo 193-0998, Japan
  • SCD Research Site
    Meguro, Tokyo 152-8902, Japan
  • SCD Research Site
    Nerima-ku, Tokyo 177-8521, Japan
  • SCD Research Site
    Ube, Yamaguti 755-8505, Japan
  • SCD Research Site
    Fukuoka, 812-0011, Japan
  • SCD Research Site
    Fukushima, 960-1295, Japan
  • SCD Research Site
    Kita, 761-0793, Japan
  • SCD Research Site
    Nagakute, 480-1195, Japan
  • SCD Research Site
    Niigata, 951-8520, Japan
  • SCD Research Site
    Saga, 849-8501, Japan
  • SCD Research Site
    Sakai, 593-8304, Japan
  • SCD Research Site
    Sakura, 285-8741, Japan
  • SCD Research Site
    Toyama, 930-0194, Japan
  • SCD Research Site
    Cheongju-si, Chungcheongbugdo 28644, Korea, Republic of
  • SCD Research Site
    Guri-si, Gyeonggido 11923, Korea, Republic of
  • SCD Research Site
    Suwon, Gyeonggido 16499, Korea, Republic of
  • SCD Research Site
    Changwon-Si, Gyeongsangnamdo 51472, Korea, Republic of
  • SCD Research Site
    Busan, 48108, Korea, Republic of
  • SCD Research Site
    Busan, 49201, Korea, Republic of
  • SCD Research Site
    Busan, 49241, Korea, Republic of
  • SCD Research Site
    Busan, 49267, Korea, Republic of
  • SCD Research Site
    Daegu, 41944, Korea, Republic of
  • SCD Research Site
    Daegu, 42415, Korea, Republic of
  • SCD Research Site
    Daegu, 42601, Korea, Republic of
  • SCD Research Site
    Daejeon, 35015, Korea, Republic of
  • SCD Research Site
    Daejeon, 35365, Korea, Republic of
  • SCD Research Site
    Gwangju, 61469, Korea, Republic of
  • SCD Research Site
    Incheon, 21565, Korea, Republic of
  • SCD Research Site
    Incheon, 22332, Korea, Republic of
  • SCD Research Site
    Jinju-si, 52727, Korea, Republic of
  • SCD Research Site
    Seoul, 02447, Korea, Republic of
  • SCD Research Site
    Seoul, 02841, Korea, Republic of
  • SCD Research Site
    Seoul, 03080, Korea, Republic of
  • SCD Research Site
    Seoul, 05355, Korea, Republic of
  • SCD Research Site
    Seoul, 05505, Korea, Republic of
  • SCD Research Site
    Seoul, 06198, Korea, Republic of
  • SCD Research Site
    Seoul, 06351, Korea, Republic of
  • SCD Research Site
    Seoul, 07441, Korea, Republic of
  • SCD Research Site
    Seoul, 7061, Korea, Republic of
  • SCD Research Site
    Jelgava, LV-3001, Latvia
  • SCD Research Site
    Riga, LV-1002, Latvia
  • SCD Research Site
    Riga, LV-1006, Latvia
  • SCD Research Site
    Riga, LV-1009, Latvia
  • SCD Research Site
    Wałbrzych, Dolnoslaskie 58-309, Poland

Showing the first 100 of 130 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Sep 2022, 24 months.

Results were first posted in Oct 2023, 1 year 1 month after primary completion.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 24 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2020
First posted
Jul 21, 2020
StartActual
Aug 13, 2020
Primary completionActual
Sep 8, 2022
CompletionActual
Sep 8, 2022
Results first posted
Oct 10, 2023
Last update
Oct 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04480463
Lead sponsor
Sam Chun Dang Pharm. Co. Ltd.
Responsible party
Sponsor
First posted
Jul 21, 2020
Start date
Aug 13, 2020
Primary completion
Sep 8, 2022
Completion
Sep 8, 2022
Results posted
Oct 10, 2023
Last update
Oct 10, 2023

Study contacts

Byung Jhip Ha
study director · Sam Chun Dang Pharm. Co. Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion